AbbVie stock slips after a $464.81 billion valuation and Q2 beat
Published on 08/27/2026 at 22:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Shares ease after the latest print
AbbVie Inc. (US00287Y1091) stock traded at $258.42 in New York on August 27, 2026, after a 1.7 percent decline in late trading. The company carried a market value of $464.81 billion and a beta of 0.30 on the same session.
In the latest reported quarter, AbbVie earned $3.65 per share on revenue of $16.99 billion, both from the quarter reported on July 31, 2026. Earnings beat consensus by $0.04 per share, while revenue topped expectations by $190 million.
The margin story still matters
Revenue rose 10.2 percent year over year in that quarter, and net margin came in at 9.80 percent. That combination leaves the market focused on how much of the top-line growth can keep flowing through to profit as the year advances.
The company also lifted Q3 2026 guidance to $3.84 to $3.88 per share, a useful marker for the next read-through on execution. The guidance range sits above the just-reported $3.65 quarter and sets a tighter band for investors to measure the next print against.
Pipeline and product mix
AbbVie's immunology and neuroscience portfolio remains the core commercial engine, with Skyrizi and Rinvoq driving a large share of current growth. In the first quarter of 2026, Skyrizi generated $5.5 billion and Rinvoq $2.5 billion, figures that show why the newer products matter more each quarter.
For investors, that mix is the key comparison: a $16.99 billion quarter and a 10.2 percent revenue increase are stronger signals than the stock's short-term swing alone. The next earnings date, if confirmed by the company, will be the next obvious checkpoint for whether the guidance range holds.
More on AbbVie
AbbVie is a global biopharmaceutical group built around immunology, oncology, neuroscience, aesthetics, and eye care. Its products include Skyrizi, Rinvoq, Humira, Vraylar, and Botox Therapeutic.
AbbVie shares and market context
As of August 27, 2026, AbbVie shares stood at $258.42 in New York. The stock's market capitalization was $464.81 billion, underscoring how much of the story now rests on earnings delivery rather than size alone.
Company details
Company: AbbVie Inc.
ISIN: US00287Y1091
Ticker: ABBV
Exchange: NYSE
Price (as of August 27, 2026, 8:26 p.m. ET): $258.42 USD
Market cap: $464.81 billion
Sector / Industry: Health Care / Biotechnology
Index membership: S&P 500
